Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2011-01-25
2011-01-25
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S423000, C514S031000, C514S182000
Reexamination Certificate
active
07875282
ABSTRACT:
Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.
REFERENCES:
patent: 3959078 (1976-05-01), Guire et al.
patent: 4350160 (1982-09-01), Kolesov et al.
patent: 4366819 (1983-01-01), Kaster
patent: 4368736 (1983-01-01), Kaster
patent: 4624257 (1986-11-01), Berggren et al.
patent: 4722906 (1988-02-01), Guire et al.
patent: 4733665 (1988-03-01), Palmaz
patent: 4739762 (1988-04-01), Palmaz
patent: 4743327 (1988-05-01), DeHaan et al.
patent: 4776337 (1988-10-01), Palmaz
patent: 4917090 (1990-04-01), Berggren et al.
patent: 4917091 (1990-04-01), Berggren et al.
patent: 5229172 (1993-07-01), Cahalan et al.
patent: 5234447 (1993-08-01), Kaster et al.
patent: 5308641 (1994-05-01), Cahalan et al.
patent: 5350800 (1994-09-01), Cahalan et al.
patent: 5415938 (1995-05-01), Cahalan et al.
patent: 5837313 (1998-11-01), Ding et al.
patent: 6099562 (2000-08-01), Ding et al.
patent: 6120536 (2000-09-01), Ding et al.
patent: 6153252 (2000-11-01), Hossainy et al.
patent: 6425898 (2002-07-01), Wilson et al.
patent: 6528150 (2003-03-01), Nazarova et al.
patent: 7419678 (2008-09-01), Falotico
patent: 2002/0188277 (2002-12-01), Roorda et al.
patent: 2003/0060877 (2003-03-01), Falotico et al.
patent: 2003/0065382 (2003-04-01), Fischell et al.
patent: 1378865 (2002-11-01), None
patent: WO 98/33443 (1998-08-01), None
patent: WO 01/87372 (2001-11-01), None
patent: WO 0287372 (2002-11-01), None
patent: WO 03/009778 (2003-02-01), None
patent: WO 03/073985 (2003-09-01), None
patent: WO 03/082368 (2003-10-01), None
European Search Report EP 05 25 1712 dated Jun. 16, 2005.
Clowes, A.W and Karnovsky M., Nature 265:25-26, 1977.
Guyton, J.R. et al., Circ. Res., 46:625-634, 1980.
Clowes, A.W. and Clowes, M.M., Lab. Invest. 52:611-616, 1985.
Clowes, A.W. and Clowes, M.M., Circ. Res. 58:839-845, 1986.
Majesky et al., Circ. Res. 61:296-300, 1987.
Snow et al., Am. J. Pathol. 137:313-330, 1990.
Okada T. et al., Neurosurgery 25: 92-98, 1989.
Currier, J.W. et al., Circ. 80:11-66; 1989.
Sollot, S.J. et al., J. Clin. Invest. 95: 1869-1876, 1995.
Powell, J. S. et al., Science, 245: 186-188, 1989.
Lundergan, C. F. et al., Am J. Cardio. 17 (Suppl. B): 132B-136B, 1991.
Jonasson, I. et al., Proc. Natl., Acad. Sci., 85: 2303, 1988.
Ferns, G.A.A., et al., Science 253: 1129-1132, 1991.
Nemecek, G.M. et al., J. Pharmacol Exp.Thera. 248: 1167-1174, 1989.
Liu, M.W. et al., Circ. 81: 1089-1093, 1990.
Fukuyama, J. et al., Eur. J. Pharmacol. 318: 327-332, 1996.
Hansson, G.K. and Holm, J. Circ. 84: 1266-1272, 1991.
Marx, S.O. et al., Circ. Res. 76: 412-417, 1995.
Colburn, M.D. et al., J. Vasc. Surg. 15: 510-518, 1992.
Berk, B.C. et al., J. Am. Coll. Cardiol. 17: 111B-117B, 1991.
Weinberger, J. et al., Int. J. Rad. Onc. Biol. Phys. 36: 767-775, 1996.
Farb, A. et al., Circ. Res. 80:542-550, 1997.
Simons, M. et al., Nature 359: 67-70, 1992.
Chang, M.W. et al., J. Clin. Invest. 96: 2260-2268, 1995.
Modern Fluoropolymers, (J Shires ed.), John Wiley & Sons, New York, 1997, pp. 77-87.
Ajroldi, et al., Fluoroelastomers-dependence of relaxation Phenomena on Compositions, Polymer 30, 2180, 1989.
Hanson & Harker, Proc. Natl. Acad. Sci. USA 85:3184-3188, 1988.
Woo et al., J. Med Chem, 45:2877-2885, 2002.
Deroanne et al., Oncogene 21(3): 427-436, 2002.
Carrera et al., J. Clin. Invest. 86:1480-1488, 1990.
Carson et al., Blood 62:737-743, 1983.
Mooberry, Susan L.: “Mechanism of action of 2-methoxyestradiol: new developments” Drug Resistance Updates, Volume Date 2003, 6 (6), 355-361 Coden: Drupfw; ISSN: 1368-7646, 2004, XP002332139.
Nishigaki, I. et al: “Anti-proliferative effect of 2-methoxyestradiol on cultured smooth muscle cells from rabbit aorta” Atherosclerosis (Shannon, Ireland), 113 (2), 167-70 Coden: Athsbl; ISSN: 0021-9150, 1995 XP002332157.
Beutler, E. “Cladribine (2-chlorodeoxyadenosine)”, The Lancet, vol. 340, p. 952 (Oct. 1992).
Brehm, B., et al. “β-Blockers of the Third Generation Inhibit Endothelin-1 Liberation, mRNA production and Proliferation of Human Coronary Smooth Muscle and Endothelial Cells”, Journal of Cardiovascular Pharmacology, 36 (Suppl. 1):S401-S-403 (2000).
Brehm, B., et al. “Chronically Elevated Endothelin-1 Concentrations Modulate the β-Adrenergic Receptor System In Vitro and In Vivo”, Journal of Cardiovascular Pharmacology, 36 (Suppl. 1):S157-159 (2000).
Campbell & Campbell, “Phenotypic Modulation of Smooth Muscle Cells in Primary Culture”, (Table of Contents), Chapter 2, vol. 1, pp. 39-52 (1985).
Campbell & Campbell, “Cell Biology of Smooth Muscle in Culture: Implications for Atherogenesis”, Inter. Angio, 6 pp. 73 (1987).
Carson, D., et al. “DNA Strand Breaks, NAD Metabolism, and Programmed Cell Death”, Experimental Cell Research 164 p. 273-281 (1986).
Clowes and Schwartz, “Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery”, Cir. Res. 56: 139-145 (1985).
Edelman, E., et al. “Pathobiologic Responses to Stenting”, American journal of Cardiology vol. 91, Issue 7, Suppl. 1 (Apr. 1998) pp. 4E-6E.
Fischman, D., et al. “A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease”, The New England Journal of Medicine, vol. 331:496-501 (1994).
Franklin, S., et al. “Pharmacologic Prevention of Restenosis After Coronary Angioplasty: Review of the Randomized Clinical Trials”, Coronary Artery Disease, vol. 4, No. 3 (Mar. 1993).
Lang, R., et al. “Effects of Okadaic Acid and ATPγS on Cell Length and CA2+—Channel Currents Recorded in single Smooth Muscle Cells of the Guinea-Pig Taenia Caeci”, Br. J. Pharmacol. 104, p. 331-336 (1991).
Mak, K., et al. “Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization”, Department of Cardiolog, Cleveland Clinical Foundation, Ohio p. 255 (1991).
Pompa, J., et al. “Clinical Trials of Restenosis After Coronary Angioplasty”, Journal of the American Heart Association (Circulation), 84:1426-1436 (1991).
Serruys, P. et al. “Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty. A Multicenter Randomized double-Blind Placebo-Controlled Trial”, Circulation of the Journal of the American Heart Association, 88 p. 1588-1601 (1993).
Serruys, P., et al. “Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study”, Circulation of the American Heart Association, vol. 93(3) p. 412-422 (1996).
Serruys, P., et al. “A Comparison of Balloon-Expandable-Stent Implantation with Ball
Falotico Robert
Parry Tom Jay
Zhao Jonathon Z.
Cordis Corporation
Evens Carl
Weddington Kevin
LandOfFree
Coated medical device for local vascular delivery of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Coated medical device for local vascular delivery of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Coated medical device for local vascular delivery of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2736265